Pykus Therapeutics secures a new patent retinal sealant, PYK-2101

(Image credit: AdobeStock/jittawit.21)

Pykus Therapeutics has secured a new patent from the United States Patent and Trademark Office entitled "Hydrogel Formulations and Methods and Devices for Administration of the Same" (US Patent No. 12,233,157). This will apply to the company’s next-generation biodegradable retinal sealant, PYK-2101 and is expected to provide robust protection of Pykus' lead clinical-stage asset into 2044.¹

PYK-2101 is a first-in-class biodegradable retinal hydrogel sealant. The company is pursuing an initial indication for the treatment of retinal detachment; PYK-2101 offers the opportunity to dramatically improve and accelerate visual recovery following retinal detachment surgery by sealing retinal breaks directly without having to obscure vision, while also eliminating the need for patients to have to position "face-down" after surgery. This change to is expected to enhance the patient experience and improve surgical outcomes.¹

Currently, PYK-2101 is being investigated in a prospective, multicenter clinical trial in patients with retinal detachment in Australia. The company anticipates providing a clinical update of its ongoing trial in the second quarter of of 2025.¹

Reference:

1. Pykus Therapeutics Expands Patent Portfolio for PYK-2101, a First-in-class Retinal Sealant Delivery Technology. Pykus Therapeutics, Inc. February 26, 2025. Accessed February 28, 2025. https://www.wsav.com/business/press-releases/cision/20250226SF27740/pykus-therapeutics-expands-patent-portfolio-for-pyk-2101-a-first-in-class-retinal-sealant-delivery-technology/